Ocular Corticosteroid Options
Prednisolone acetate 1% topical drops should be the first-line ocular corticosteroid for active anterior uveitis, dosed initially at higher frequencies (up to every 1-2 hours while awake for severe inflammation) then tapered based on clinical response, with mandatory intraocular pressure monitoring within 1 month of initiation and every 3 months during stable therapy. 1, 2
Recommended Corticosteroid Agents
First-Line: Prednisolone Acetate 1%
Prednisolone acetate 1% is conditionally recommended over difluprednate due to superior corneal penetration and more established safety profile, despite difluprednate's higher potency 1, 2. The higher potency of difluprednate increases risks of corticosteroid-induced intraocular pressure elevation and cataract formation 2. However, prednisolone acetate 1% requires more frequent dosing due to lower potency—a compliance consideration that must be weighed against safety 2.
Alternative Agents
- Loteprednol etabonate: Newer-generation corticosteroid with similar anti-inflammatory efficacy to prednisolone but significantly lower IOP elevation risk due to rapid de-esterification to inactive metabolites 3, 4. Consider for patients at high risk for steroid response or requiring longer-term therapy.
- Difluprednate: Reserve for cases requiring maximum potency when prednisolone acetate proves insufficient, but use with heightened IOP monitoring 2.
Dosing Regimens
Initial Dosing for Active Inflammation
- Severe inflammation: Start prednisolone acetate 1% every 1-2 hours while awake
- Moderate inflammation: 4-6 times daily
- Mild inflammation: 2-4 times daily
Doses greater than 1-2 drops/eye/day increase risk for ocular complications and should be used only as short-term therapy (≤3 months) 1.
Maintenance Threshold
If patients require 1-2 drops/day of prednisolone acetate 1% (or equivalent) for ≥3 months to maintain control, systemic therapy should be added or escalated 1, 2. This threshold exists because prolonged topical steroid use at this frequency significantly increases risks of glaucoma and cataracts 1, 2.
Tapering Schedules
Algorithmic Approach to Tapering
Step 1: Achieve Control
- Continue initial high-frequency dosing until anterior chamber cells decrease to <1+ (fewer than 6-15 cells per 1mm × 1mm slit beam) 1
Step 2: Begin Taper
- Once inflammation controlled, reduce frequency by 1 drop per day every 1-2 weeks
- Monitor within 1 month after each change in topical glucocorticoid dosing (strong recommendation) 2
Step 3: Decision Point at 1-2 Drops Daily
- Not on systemic therapy: Add systemic therapy (methotrexate or mycophenolate) to facilitate steroid taper 1, 2
- Already on systemic therapy for ≥3 months: Change or escalate systemic therapy 1, 2
Step 4: Goal
- Complete discontinuation of topical corticosteroids due to glaucoma and cataract risks 1
Common Pitfall
Do not maintain patients on 1-2 drops/day indefinitely without systemic therapy—this represents inadequate disease control and exposes patients to cumulative steroid complications 2.
Intraocular Pressure Monitoring Protocol
Mandatory Monitoring Schedule
Baseline: Measure IOP before initiating corticosteroids 5
During Tapering:
- Within 1 month after each change in topical glucocorticoid dosing (strong recommendation) 2
- This frequent monitoring is critical as IOP elevation can occur rapidly with dose changes
Stable Therapy:
- Every 3 months minimum (strong recommendation) 2
After Systemic Therapy Changes:
- Within 2 months of changing systemic therapy 2
Risk Stratification for IOP Elevation
High-risk patients requiring more frequent monitoring:
- ≥2 drops/day of prednisolone acetate (strong risk factor for IOP elevation) 2
- Treatment duration >4 weeks 6
- Personal or family history of glaucoma
- High myopia
- Diabetes mellitus
- Connective tissue disease
Long-Term Risk Data
With long-term prednisolone acetate 1% use (as studied in post-keratoplasty patients), cumulative risks of steroid-induced ocular hypertension are substantial: 29% at 1 year, 41% at 5 years, and 49% at 10 years 6. Among those developing ocular hypertension, 25% required glaucoma treatment by 10 years, with 20% needing filtration surgery 6.
Management of IOP Elevation
Definition of steroid-induced ocular hypertension: IOP ≥24 mmHg OR increase ≥10 mmHg over baseline 6
Management algorithm:
- First response: Reduce corticosteroid frequency or switch to lower-potency agent (loteprednol etabonate)
- If inflammation control permits: Discontinue topical steroids
- If IOP remains elevated: Initiate topical glaucoma medications
- Refractory cases: Consider filtration surgery (required in 20% of long-term users with ocular hypertension) 6
Special Considerations
Periocular and Intraocular Injections
The guidelines defer periocular and intraocular corticosteroid injections to ophthalmologist discretion 1. However, research indicates:
- Intravitreal triamcinolone: Effective for refractory macular edema but transient effect (~3 months) with higher rates of cataract and IOP elevation versus periocular injections 7
- Sustained-release implants: Available for chronic posterior uveitis but associated with very high rates of IOP elevation and cataract formation 7
Systemic Corticosteroids
In selected complicated patients, systemic glucocorticoids can be used as short-term bridging therapy 1. However, adding or increasing topical glucocorticoids for short-term control is conditionally recommended over adding systemic glucocorticoids 1, 2.
Cataract Risk
While IOP monitoring is emphasized, cataract formation risk also increases with ≥4 drops daily 2. The evidence for cataract formation with short-term use (<4 weeks) is uncertain 8, but long-term use substantially increases risk 6.
Pediatric Considerations
In children with autoimmune conditions requiring long-term oral corticosteroids, almost two-thirds develop raised intraocular pressure, mostly asymptomatically 5. This underscores the importance of baseline and periodic ophthalmic examinations including IOP measurements in all patients on corticosteroid therapy 5.